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Abstract
Background: ACE2 is a novel homologue of angiotensin converting enzyme (ACE). ACE2 is highly
expressed in human heart and animal data suggest that ACE2 is an essential regulator of cardiac
function in vivo. Since overactivity of the renin-angiotensin system contributes to the progression
of heart failure, this investigation assessed changes in gene expression of ACE2, ACE, AT1 receptor
and renin in the human failing heart.
Methods: The sensitive technique of quantitative reverse transcriptase polymerase chain reaction
was used to determine the level of mRNA expression of ACE and ACE2 in human ventricular
myocardium from donors with non-diseased hearts (n = 9), idiopathic dilated cardiomyopathy
(IDC, n = 11) and ischemic cardiomyopathy (ICM, n = 12). Following logarithmic transformation of
the data, a one-way analysis of variance was performed for each target gene followed by a Dunnett's
test to compare the two disease groups IDC and ICM versus control.
Results: As anticipated, ACE mRNA was found to be significantly increased in the failing heart with
a 3.1 and 2.4-fold up-regulation found in IDC and ICM relative to non-diseased myocardium.
Expression of ACE2 mRNA was also significantly up-regulated in IDC (2.4-fold increase) and ICM
(1.8-fold increase) versus non-diseased myocardium. No change in angiotensin AT1 receptor
mRNA expression was found in failing myocardium and renin mRNA was not detected.
Conclusions: These data suggest that ACE2 is up-regulated in human IDC and ICM and are
consistent with the hypothesis that differential regulation of this enzyme may have important
functional consequences in heart failure. This strengthens the hypothesis that ACE2 may be a
relevant target for the treatment of heart failure and will hopefully spur further studies to clarify
the functional effects in human myocardium of ACE2 derived peptides.
Background
Angiotensin converting enzyme (ACE) catalyses the for-
mation of angiotensin II (Ang II) and thereby plays a key
role in cardiorenal regulation and blood pressure control.
Overactivity of the renin-angiotensin system contributes
to the pathophysiology of hypertension and heart failure,
which is reflected in the use of ACE inhibitors in the treat-
ment of these conditions. Interestingly, ACE2, a novel
homolog of ACE, has recently been identified by two
independent groups [1,2]. ACE2 is a membrane-associ-
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ated carboxypeptidase which is highly expressed in
human heart, kidney, testis [1,2] and gastrointestinal sys-
tem [3]. ACE2 contains a single catalytic domain that is
42% identical to that of ACE. Importantly, ACE2 shows a
markedly different substrate preference than ACE. Thus,
of the key peptides of the renin-angiotensin system, ACE2
only cleaves Ang II with high catalytic efficiency [4],
although ACE2 does have affinity for Ang I and can there-
fore compete with ACE for this substrate. In addition, the
key product resulting from ACE2-induced hydrolysis of
Ang II is Ang 1-7 [2,4], whose functional effects (vasodila-
tor, anti-proliferative) oppose those of Ang II [5,6]. Taken
together, these data are shaping the hypothesis that ACE2
may act to balance the activity of the renin-angiotensin
system [7]. This is complemented by an important recent
functional study [8], which demonstrated that ACE2
mRNA levels are reduced in several strains of hypertensive
rats. Furthermore, Crackower et al. demonstrated that tar-
geted disruption of ACE2 in mice results in a cardiac con-
tractility defect, increased cardiac levels of Ang II and up-
regulation of hypoxia-inducible genes in the heart [8].
Therefore, given the evidence that ACE2 may be an impor-
tant regulator of the renin-angiotensin system and cardiac
function, this study used the highly sensitive technique of
real time quantitative reverse transcriptase PCR (QRT-
PCR) to probe whether ACE2 and other components of
the renin-angiotensin system are differentially regulated
in the human failing heart.
Methods
Samples of human left ventricular free wall, which had
been snap frozen and stored at -80°C, were selected based
on the donor's clinical history and histological examina-
tion of the ventricular samples by a qualified pathologist.
Tissues were obtained with approval from the appropriate
ethics committees and in all cases with the full informed
consent of the donor or their next of kin. The tissues were
classified as Group 1, control, non diseased; Group 2, idi-
opathic dilated cardiomyopathy (IDC); Group 3,
ischemic cardiomyopathy (ICM) (see Table 1 for donor
information). All samples for groups 2 and 3 were
obtained from hearts removed at transplantation. RNA
was extracted using TriZol (Invitrogen Life Technologies)
according to the manufacturer's protocols. Determining
the optical density at 260 and 280 nm assessed the con-
centration and purity of the RNA, with only RNA yielding
a ratio greater than 1:7 (260 : 280 nm) being used. All
RNA solutions were diluted to 1 ug/ul in nuclease free
water containing RNase inhibitor (N808-0119 Applied
Biosystems). The quality of total RNA was further assessed
by two methods. Firstly the RNA samples were run down
denaturing agarose gels and only samples that had intact
18S and 28S ribosomal bands were used. Secondly, it was
determined whether the samples were able to produce
robust amplification of actin and transferrin receptor
mRNA transcripts.
Detection of mRNA was by QRT-PCR (ABI Prism 7700
Sequence Detection System; Applied Biosystems) as previ-
ously described [9]. Forward and reverse primers and
fluorogenic probes (see Table 2) were designed using
Primer Express software (Applied Biosystems). The primer
probe set for each gene was designed so that it crosses two
exons, thereby amplifying cDNA and not genomic DNA.
In every PCR reaction, the level of the housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was also determined. Duplexing the assay with GAPDH
further confirms sample integrity and excludes the possi-
bility of the low expression of genes of interest being a
result of sample degradation. In all samples used in the
current study, GAPDH was greater than 1 × 104 copies,
indicating high quality mRNA. The copy number of each
target gene was expressed as absolute copies per 100 ng of
total RNA.
For the statistical analysis a logarithmic transformation
(log to the base 10) of the data was carried out because
this data is log-normally distributed. A two-way analysis
of covariance (using the Genstat statistical software) dem-
onstrated that the GAPDH Ct values contribute to the
analysis as covariates by reducing the background noise
against which to measure the differences between the con-
trol and disease groups, thereby increasing sensitivity.
However, the significance of the TargetGene × Group
interaction term (p = 0.013) indicates that the group dif-
ferences are not consistent across the target genes. Thus a
separate one-way analysis of covariance of each target
gene was preferable (using the Cellula software). As a
post-hoc test to allow for multiple comparisons, Dun-
nett's test was carried out comparing both of the disease
groups, IDC and ICM, versus the control group. Statistical
significance was assigned at P < 0.05.
Results
Atrial natriuretic factor (ANF) mRNA was evaluated as a
positive control and was confirmed to be up-regulated by
approximately 13 and 8-fold in IDC and ICM, respec-
tively, versus the control group (see Table 3; Figure 1).
Also in accordance with previous reports, relative to non-
diseased ventricle, ACE mRNA was increased approxi-
mately 3-fold and 2-fold in IDC and ICM, respectively.
ACE2 mRNA was expressed in non-diseased ventricle (see
Table 3, Figure 1) and expression was further enhanced in
IDC (~2 fold increase) and ICM (~2-fold increase).
Expression of the angiotensin AT1 receptor mRNA was not
changed in either of the heart failure groups relative to
control. Renin mRNA was not present (zero copies) in
ventricle from either of the groups. The renin primer
probe set was validated by demonstrating expression ofBMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/19
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Table 1: Donor details
Group Donor Sex Age LVEF (%) Therapeutic history
Cont (BT) 1 F 42 N/A N.K.
Cont (SAH) 2 F 48 N/A N.K.
Cont (SAH) 3 F 51 N/A N.K.
Cont (HT) 4 M 31 N/A N.K.
Cont (SEP) 5 F 3 N/A N.K.
Cont (SAH) 6 M 25 N/A N.K.
Cont (HT) 7 F 23 N/A A-DE; A-DI; BET; SYM
Cont (SAH) 8 M 25 N/A N.K.
Cont (SAH) 9 M 50 N/A N.K.
IDC 10 M 49 11 ACE; CAL; DIG; DIU
IDC 11 M 64 17 ACE; A-CO; CAL; DIG; DIU; NIT
IDC 12 M 19 N/A LVAD
IDC 13 M 41 5 A-AR; ACE; A-CO; A-IN; DIU
IDC 14 M 58 24 ACE; A-CO; ALD; DIU; XAN
IDC 15 M 52 28 A-AR; ACE; A-HI; AST; DIU;
IDC 16 M 17 N/A LVAD. DIU; SYM
IDC 17 M 56 16 ACE; A-CO; A-IN; DIG; DIU
IDC 18 M 17 N/A ACE; DIU; PDE; SYM
IDC 19 F 58 20 ACE; A-CO; DIU; NIT
IDC 20 M 51 27 A-CO; ALD; ANG; DIU;
ICM 21 F 60 25 ACE; DIG; DIU; LIP
ICM 22 M 48 15 ACE; A-CO; DIU;
ICM 23 F 51 57 A-IN; BET; CAL; LIP; NIT
ICM 24 M 56 13 ACE; A-DI; A-IN; DIU; LIP
ICM 25 M 54 21 A-AR; ACE; A-IN; DIG; DIU; LIP
ICM 26 M 56 30 A-HI; A-IN; DIU
ICM 27 F 55 N/A ACE; A-DE; A-DI; ALD; DIU
ICM 28 M 48 15 ACE; DIU; LIP
ICM 29 F 62 20.5 A-AR; ACE; ALD; A-IN; DIU; LIP
ICM 30 M 56 18 A-NE; DIG; DIU
ICM 31 M 56 N/A A-CO; ALD; ANG; DIG; DIU; LIP
ICM 32 M 50 10 ACE; A-CO; ALD; DIG; DIU
LVEF, Left ventricular ejection fraction. Cont, Control (cause of death is shown in parentheses); IDC, idiopathic dilated cardiomyopathy; ICM, 
ischemic cardiomyopathy; BT, brain tumour; SAH, subarachnoid haemorrhage; HT, head trauma; SEP, sepsis following rupture of appendix. N/A, 
not available. LVAD, Left ventricular assist device. N.K., Not known. ACE, ACE inhibitor; ALD, Aldosterone antagonist; A-AR, Anti-arrhythmic; A-
CO, Anti-coagulation; A-DE, Anti-depressant; A-DI, Anti-diabetic; A-HI, Anti-histamine; A-IN, Anti-inflammatory; A-NE, Anti-neoplastic; ANG, 
Angiotensin II receptor antagonist; AST, Asthma treatment; BET, Beta blocker; CAL, Calcium channel blocker; DIG, Digoxin; DIU, Diuretic; LIP, 
Lipid lowering agent; NIT, Nitrate; PDE, PDE III inhibitor; SYM, Sympathomimetic; XAN, Xanthine oxidase inhibitor.
Table 2: Target accession numbers and coding sequences
Target Genbank 
Accession 
no.
Forward Probe Reverse
ACE2 AF291820 5'-CATTGGAGCAAG TGTTGGATCTT-3' 5'-CTTGCAGCTACACC AGTTCCCAGGCA-3' 5'-GAGCTAATGCATG CCATTCTCA-3'
ACE J04144 5'-TCGGCCATGTTGA GCTACTTC-3' 5'-AGCCGCTGCTGGAC TGGCTCC-3' 5'-TCCCCATGCAGCT CGTTC-3'
ANF M54947 5'-ACCGTGAGCTTCC TCCTTTTACT-3' 5'-CATTCCAGCTCCTA GGTCAGACCAGAGCT AA-3' 5'-TTGGACACGGCAT TGTACATG-3'
AT1 Z11162 5'-GCATTGATCGATA CCTGGCTATT-3' 5'-AAGTCCCGCCTTCG ACGCACAA-3' 5'-AGCAGCCAAATGA TGATGCA-3'
RENIN L00073 5'-GCCACCTTCATCC GAAAGTTC-3' 5'-ACACAGAGTTTGAT CGGCGTAACAACCG-3' 5'-GCCAAGGCGAAG CCAAT-3'BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/19
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renin mRNA (mean copy number = 1158) in human renal
cortex from three donors.
Discussion
First identified in 2000, ACE2 is known to be highly
expressed in human heart and may act to oppose the activ-
ity of the renin-angiotensin system by converting Ang II to
the vasodilator Ang I-7 and by competing with ACE for
Ang I [1,2,4,10]. In addition, recent animal data suggest
that ACE2 can modulate cardiac contractility, suppress
cardiac Ang II levels and down-regulate hypoxia-induced
pro-apoptotic genes [8], pointing to a role for ACE2-
derived peptides in the regulation of cardiac function.
Given that overactivity of the renin-angiotensin system is
implicated in the pathophysiology of chronic heart fail-
ure, this study explored whether cardiac ACE2 may be dif-
ferentially regulated in this condition. The technique of
QRT-PCR was applied as we have found this to be the
most quantitative and sensitive technique for probing
changes in the expression of specific genes in human tis-
sues [11].
To validate the use of QRT-PCR to identify differentially
regulated genes in heart failure, ANF was studied as a pos-
itive control. As previously reported [12], ANF mRNA was
found to be abundantly expressed in left ventricular myo-
cardium and to be up-regulated in idiopathic dilated car-
diomyopathy. ANF mRNA expression was also 8-fold up-
regulated in the ischemic cardiomyopathy group
although the change (relative to control) narrowly missed
being statistically significant (P = 0.058). Several compo-
nents of the renin-angiotensin system were subsequently
studied. In agreement with previous workers [13], ACE
mRNA was found to be up-regulated in both forms of
heart failure, in accordance with the hypothesis that local
production of Ang II is enhanced in the failing heart.
Interestingly, ACE2 appeared more highly expressed than
ACE in the non-failing ventricle and, like ACE, the levels
of ACE2 mRNA were found to be significantly increased in
idiopathic and ischemic cardiomyopathy.
The observation that ACE2 appears more highly expressed
than ACE in human left ventricle should be interpreted
cautiously as differences in primer probe set efficiencies
can make difficult the quantitative comparison of expres-
sion levels of different targets. In this case, primer probe
sets for ACE and ACE2 are believed to be of similar effi-
ciency since they gave similar threshold values when used
in a quantitative PCR with 10,000 genomic equivalents as
the template. Therefore, the current data coupled to previ-
ous reports [3,14] suggests that the relative expression lev-
els of ACE:ACE2 mRNA is likely to vary significantly
dependent on the species and tissue.
Unlike mRNA expression for ACE and ACE2, that of the
angiotensin AT1 receptor was not found to be differen-
tially expressed in failing myocardium. This contrasts with
previous data [15,16] indicating reduced AT1receptor
expression in heart failure. Since the latter studies were
carried out on right ventricular biopsies, it is possible that
regional variation occurs in ventricular AT1  receptor
expression in the failing heart. Finally, in contrast to all
other genes studied, no expression (zero copies) of renin
mRNA was detected in either non-failing or failing left
ventricular myocardium. The question of whether renin
may be produced locally in the myocardium has been an
issue of controversy over the years but has not to our
knowledge previously been addressed using QRT-PCR.
However, even with this sensitive detection methodology,
no ventricular expression (zero copies) was detected. This
was not a methodology failure as the primer probe set
used for renin transcript amplification worked as expected
in human renal cortex. Therefore, these data are in
agreement with previous findings [17], suggesting that the
renin gene is not expressed in cardiac tissues.
Therefore, the key novel result from the current work is
that ACE2 mRNA expression is increased in the human
failing heart. This finding sits well with the emerging
hypothesis that ACE2 may counterbalance the effects of
stimulation of the renin-angiotensin system by reducing
Ang II levels, and generating peptide products such as
Ang1-7, which may benefit cardiac function. Indeed,
recent data suggest that administration of Ang 1-7 can
ameliorate the development of ischemia-induced heart
failure in rats [18,19]. Since the completion of the current
study, it has been discovered that the G protein coupled
receptor, Mas, is a high affinity, functional receptor for
Ang 1-7 [20]. The question of whether Mas, like ACE2, is
also differentially regulated in heart failure will be an
interesting subject for future studies to address. Whether
up regulation of ACE2 has important functional
consequences in the human failing heart remains to be
determined, however, the emerging data raise the intrigu-
ing possibility that a novel therapeutic approach to heart
failure may be achieved through enhancement of ACE2
activity.
It is worth noting some limitations of the current work.
First, only changes in mRNA have been addressed. While
in the case of ACE and ANF it has been shown by other
workers that in the failing heart increased mRNA trans-
lates into increased protein, this remains to be proven for
ACE2. In addition, it will be of interest to determine
which cell types in the failing heart increase the expression
of ACE2 mRNA and protein. Secondly, while the experi-
mental groups were matched for sex and age as closely as
possible, the donors in both the heart failure groups were
receiving various pharmacological therapies. Thus, weBMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/19
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Quantitative expression profile of ACE2; ACE; ANF and AT1 in control; IDC and ICM human left ventricular myocardium Figure 1
Quantitative expression profile of ACE2; ACE; ANF and AT1 in control; IDC and ICM human left ventricular 
myocardium. ACE2; ACE; ANF and AT1 mRNA copy number in human left ventricular myocardium classified as Control 
(non-diseased) (n = 9); IDC-idiopathic dilated cardiomyopathy (n = 11); ICM-ischemic cardiomyopathy (n = 12). Correspond-
ing levels of the housekeeping gene GAPDH are also shown. Each bar represents the geometric mean mRNA copy number 
with 95 % CI on a log scale. * – P < 0.05 Vs. Control.
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must acknowledge the possibility that these therapies
could have influenced the levels of expression of ACE2
mRNA. Clarification of this question will likely require
studies in animal models of heart failure where back-
ground can be strictly controlled. Finally, only end stage
heart failure has been examined in this study, thereby giv-
ing no temporal data regarding the expression of ACE2
during the development of failure.
Conclusion
This study demonstrates that increased expression of
ACE2 mRNA occurs in the human failing myocardium.
This strengthens the hypothesis that ACE2 may be a rele-
vant target for the treatment of heart failure and will
hopefully spur further studies to clarify the functional
effects in human myocardium of ACE2 derived peptides.
Competing interests
None declared.
Authors' contributions
AG and KC participated in the hypothesis generation,
experimental design, statistical analysis and writing of the
manuscript. MG participated in collection of the study
material, collation of donors' clinical history and scien-
tific discussion. JA participated in RNA extraction and set-
ting up and performance of QRT-PCR. All authors have
read and approved the final version of the manuscript.
Acknowledgements
Thank you to PRISM Training & Consultancy Ltd; http://www.pris 
mtc.co.uk(Ian Macpherson and Paul Nelson) for their advice and assistance 
in statistical analysis.
References
1. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano
N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE,
Acton S: A novel angiotensin-converting enzyme-related car-
boxypeptidase (ACE2) converts angiotensin I to angiotensin
1–9. Circ Res 2000, 87:E1-9.
2. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ: A
human homolog of angiotensin-converting enzyme. Cloning
and functional expression as a captopril-insensitive
carboxypeptidase. J Biol Chem 2000, 275:33238-33243.
3. Harmer D, Gilbert M, Borman R, Clark KL: Quantitative mRNA
expression profiling of ACE 2, a novel homologue of angi-
otensin converting enzyme. FEBS Lett 2002, 532:107-110.
4. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Par-
sons T, Baronas E, Hsieh F, Acton S, Patane M, Nichols A, Tummino
P: Hydrolysis of biological peptides by human angiotensin-
converting enzyme-related carboxypeptidase.  J Biol Chem
2002, 277:14838-14843.
5. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI: Coun-
terregulatory actions of angiotensin-(1–7). Hypertension 1997,
30:535-541.
6. Ferrario CM: Angiotension-(1–7) and antihypertensive
mechanisms. J Nephrol 1998, 11:278-283.
7. Boehm M, Nabel EG: Angiotensin-converting enzyme 2-a new
cardiac regulator. N Engl J Med 2002, 347:1795-1797.
8. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE,
Oliveira-dos-Santos AJ, da Costa J, Zhang L, Pei Y, Scholey J, Ferrario
CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y, Penninger JM:
Angiotensin-converting enzyme 2 is an essential regulator of
heart function. Nature 2002, 417:822-828.
9. Bowen WP, Carey JE, Miah A, McMurray HF, Munday PW, James RS,
Coleman RA, Brown AM: Measurement of cytochrome P450
gene induction in human hepatocytes using quantitative
real-time reverse transcriptase-polymerase chain reaction.
Drug Metab Dispos 2000, 28:781-788.
10. Oudit GY, Crackower MA, Backx PH, Penninger JM: The Role of
ACE2 in Cardiovascular Physiology. Trends Cardiovasc Med 2003,
13:93-101.
11. Coleman RA, Clark KL: Target validation using human tissue:
from gene expression to function. Targets 2003, 2:58-64.
12. Saito Y, Nakao K, Arai H, Nishimura K, Okumura K, Obata K, Take-
mura G, Fujiwara H, Sugawara A, Yamada T, et al.: Augmented
expression of atrial natriuretic polypeptide gene in ventricle
of human failing heart. J Clin Invest 1989, 83:298-305.
13. Studer R, Reinecke H, Muller B, Holtz J, Just H, Drexler H: Increased
angiotensin-I converting enzyme gene expression in the fail-
ing human heart. Quantification by competitive RNA
polymerase chain reaction. J Clin Invest 1994, 94:301-310.
14. Tikellis C, Johnston CI, Forbes JM, Burns WC, Burrell LM, Risvanis J,
Cooper ME: Characterization of renal angiotensin-converting
enzyme 2 in diabetic nephropathy.  Hypertension 2003,
41:392-397.
15. Haywood GA, Gullestad L, Katsuya T, Hutchinson HG, Pratt RE,
Horiuchi M, Fowler MB: AT1 and AT2 angiotensin receptor
gene expression in human heart failure.  Circulation 1997,
95:1201-1206.
Table 3: Quantitative gene (mRNA) expression data in ventricular samples from a background of no cardiac disease (Control), 
idiopathic cardiomyopathy (IDC) and ischemic cardiomyopathy (ICM).
Target Copy number with 95% CI
Control
(n = 9)
IDC
(n = 11)
∆ from
Control
ICM
(n = 12)
∆ from Control
ACE2 3,978
(2,102–5,531)
9,612†
(5,873–15,734)
2.4 7,338†
(5,304–10,153)
1.8
ACE 720
(349–1,484)
2,239†
(1,343–3,735)
3.1 1,692†
(1,295–2,211)
2.4
ANF 19,547
(4,377–87,287)
248,243†
(57,940–10,635,486)
12.7 151,551
(57,743–397,759)
7.8
AT1 623
(456–850)
594
(347–1,020)
0.95 541
(352–829)
0.87
RENIN 00 0
Values are geometric mean copy number for each gene/100 ng total RNA. † – P < 0.05 disease group Vs. Control.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/19
Page 7 of 7
(page number not for citation purposes)
16. Regitz-Zagrosek V, Fielitz J, Dreysse R, Hildebrandt AG, Fleck E:
Angiotensin receptor type 1 mRNA in human right ventricu-
lar endomyocardial biopsies: downregulation in heart
failure. Cardiovasc Res 1997, 35:99-105.
17. von Lutterotti N, Catanzaro DF, Sealey JE, Laragh JH: Renin is not
synthesized by cardiac and extrarenal vascular tissues. A
review of experimental evidence. Circulation 1994, 89:458-470.
18. Ferrario CM: Does angiotensin-(1–7) contribute to cardiac
adaptation and preservation of endothelial function in heart
failure? Circulation 2002, 105:1523-1525.
19. Loot AE, Roks AJ, Henning RH, Tio RA, Suurmeijer AJ, Boomsma F,
van Gilst WH: Angiotensin-(1–7) attenuates the development
of heart failure after myocardial infarction in rats. Circulation
2002, 105:1548-1550.
20. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de
Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes
EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R,
Walther T: Angiotensin-(1–7) is an endogenous ligand for the
G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003,
100:8258-8263.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1741-7015/2/19/prepub